Contents

	Contributors Preface			
1.	Translation of cancer immunotherapy from the bench to the bedside Qianyu Guo, Fan Huang, Christophe Goncalves, Sonia V. del Rincón, and Wilson H. Miller Jr			
	 Overview of components in the tumor microenvironment (TME) CTLA4 and PD-1 signaling Novel immune checkpoints Cytokine therapies Combination of small molecules and immunotherapy Neoantigen cancer vaccines Oncolytic viruses Concluding remarks References 	13 18 29 30 43 44 46 47		
2.	From immune checkpoints to vaccines: The past, present and future of cancer immunotherapy Arsen Osipov, Adrian Murphy, and Lei Zheng	63		
	 Introduction Principles of cancer immunology Progress in cancer immunotherapy Challenge in cancer immunotherapy and emerging new strategies Conclusion References 	64 66 72 103 122 122		
3.	Co-stimulatory and co-inhibitory pathways in cancer immunotherapy Rachel E. O'Neill and Xuefang Cao	145		
	 Introduction Ig-superfamily receptors TIM family receptors TNF-superfamily receptors 	146 148 160 162		

	5. Concluding remarks	176
	Acknowledgments	177
	Conflict of interest	177
	Funding	177
	References	177
4.	Immunometabolism: A new target for improving cancer	
	immunotherapy	195
	Chunqing Guo, Shixian Chen, Wenjie Liu, Yibao Ma, Juan Li, Paul B. Fisher,	
	Xianjun Fang, and Xiang-Yang Wang	
	1. Introduction	196
	2. Cell metabolism: Overview	198
	3. Metabolic reprogramming in cancer	200
	4. Metabolic regulation of immune functions	209
	5. Metabolic alterations in immune cells during cancer progression	217
	6. Reprogramming metabolic pathways to potentiate cancer immunotherapy	223
	7. Concluding remarks	230
	Acknowledgments	233
	Competing interests	233
	References	234
5.	Impact of the microbiome on cancer progression and response	
	to anti-cancer therapies	255
	Claire Buchta Rosean, Tzu-Yu Feng, Francesca N. Azar, and	
	Melanie R. Rutkowski	
	1. Introduction	256
	2. Systemic outcomes associated with microbiome composition and function	257
	3. Role of microbiota in cancer initiation and progression	265
	4. Cancer therapies impacted by the microbiome	267
	5. Potential for microbial-driven therapeutics to enhance cancer treatment	
	efficacy .	279
	6. Concluding statements	283
	References	283
6.	Immunotherapy in breast cancer: Current status and future	
	directions	295
	Amrita Basu, Ganesan Ramamoorthi, Yongsheng Jia, Jon Faughn,	
	Doris Wiener, Sabrina Awshah, Krithika Kodumudi, and Brian J. Czerniecki	
	Breast cancer: General overview	297
	1. Breast carreer, dericial overview	

Contents			vii

	3. Dendritic cells: The primary APCs	316
	4. Conclusion	332
	Conflict of interest	332
	References	332
	Further reading	347
7.	Can CpG methylation serve as surrogate markers for immune	
	infiltration in cancer?	351
	Manny D. Bacolod, Francis Barany, and Paul B. Fisher	
	1. Introduction	352
	2. Methodology	354
	3. Results	356
	4. Discussion	375
	5. Expert opinion	380
	Acknowledgment	380
	References	380